As Part of the Financing Program Set up with Winance in 2019, Genomic Vision Announces the Drawdown of the Fourth Tranche & t...
18 Maio 2020 - 1:30PM
Business Wire
Regulatory News:
Genomic Vision (FR0011799907 – GV) (Paris:GV), a
biotechnology company that develops tools and services dedicated to
the analysis and control of changes in the genome, announces today
the issue of 833,333 new shares, with a nominal value of €0.10
each, at a unit price of €0.52 including premium, through the
exercise of the warrants attached to the third tranche issued on
February 13, 2020, and 5,000,000 new shares, with a nominal value
of €0.10 each, at a unit price of €0.30 including premium, within
the framework of the financing contract signed with Winance in
accordance with the approval granted by the Company’s shareholders
at the EGM of March 4, 2019.
As a result of these two transactions, the Company strengthened
its cash position and shareholders' equity by €1.9 million, and
thus has the necessary resources to develop its activities over the
entire financial year. The share capital of Genomic Vision will now
consist of 47,130,956 shares. The new shares will be freely
tradable and immediately assimilated to the existing ordinary
shares listed on the Euronext market in Paris.
The main characteristics of this financing, comprising 4
tranches of shares with equity warrants attached (ABSAs) for a
total of €5 million, are described in the Prospectus granted visa
number 19-122 by the AMF French stock market authority on March 29,
2019 comprising a Note d’opération and a Document de référence
filed with the AMF under reference number R19-004.
***
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products
and services dedicated to the analysis (structural and functional)
of genome modifications as well as to the quality and safety
control of these modifications, in particular in genome editing
technologies and biomanufacturing processes. Genomic Vision
proprietary tools, based on DNA combing technology and artificial
intelligence, provide robust quantitative measurements needed to
high confidence characterization of DNA alteration in the genome.
These tools are mainly used for monitoring DNA replication in
cancerous cell, for early cancer detection and the diagnosis of
genetic diseases. Based near Paris, in Bagneux, the Company has
approximately 30 employees. GENOMIC VISION is a public listed
company listed in compartment C of Euronext’s regulated market in
Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
ABOUT WINANCE
Winance is a global equity investor in SMEs that have a unique
competitive advantage and a capacity to deliver short and long-term
growth, in order to enable these companies to finance themselves
competitively for growth and/or working capital needs.
Website: www.winance.com
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the reference
document dated March 29, 2019 filed with the AMF under reference
number R19-004, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
Member of the CAC® Mid & Small and CAC®
All-Tradable indexes
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200518005593/en/
Genomic Vision Dominique Rémy-Renou CEO Tel.: +33 1 49 08
07 51 investisseurs@genomicvision.com
Ulysse Communication Press Relations Bruno Arabian
Tel.: +33 1 42 68 29 70 barabian@ulysse-communication.com
NewCap Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Genomic Vision (EU:GV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Genomic Vision (EU:GV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024